A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

ClinicalTrials.gov ID: NCT07554521

Public ClinicalTrials.gov record NCT07554521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (HER2)-negative, programmed death-ligand 1(PD-L1)-positive, unresectable or metastatic gastric or gastroesophageal cancer (GAC/GEA) or esophageal squamous cell carcinoma (ESCC). The study duration will be up to approximately 6 years.

Study identification

NCT ID: NCT07554521
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: BeOne Medicines; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2026
Primary completion: Dec 30, 2031
Completion: Dec 30, 2031
Last update posted: Aug 23, 2026

2026 – 2031

United States locations

U.S. sites: 8
U.S. states: 4
U.S. cities: 8

Facility	City	State	ZIP	Site status
Helios Clinical Research	Cerritos	California	90703	Recruiting
Los Angeles Cancer Network	Los Angeles	California	90017-4803	Recruiting
Brcr Coral Springs	Coral Springs	Florida	33065	Recruiting
Bioresearch Partners Holding Hialeah Hospital	Hialeah	Florida	33013-3804	Recruiting
Florida Clinical Trials Group Plantation	Plantation	Florida	33322	Recruiting
Florida Clinical Trials Group Tamarac	Tamarac	Florida	33321	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110-1010	Recruiting
Gabrail Cancer Center Research	Canton	Ohio	44718-2566	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07554521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 23, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07554521 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →